Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Haemonetics (HAE)

Haemonetics Q2 revenue rises 8.6% to $345.5 million; GAAP EPS $0.66 vs $0.48

Positive Impact 3 of 5 earnings Written later

Haemonetics reported second-quarter fiscal 2025 revenue of $345.5 million, up 8.6%, and GAAP diluted EPS of $0.66, up from $0.48 a year earlier. The company reaffirmed its fiscal 2025 adjusted EPS guidance of $4.45 to $4.75, while its organic revenue growth guidance was raised to 1% to 4% from 0% to 3%, and operating cash flow fell to $48.8 million from $99.1 million.

Key points

  • Q2 fiscal 2025 revenue was $345.5 million, up 8.6%; organic revenue rose 3.7%
  • GAAP net income was $33.8 million, or $0.66 per diluted share, versus $24.9 million, or $0.48, a year earlier
  • Adjusted EPS was $1.12, up 13.1%; fiscal 2025 adjusted EPS guidance of $4.45 to $4.75 was reaffirmed
  • Operating cash flow was $48.8 million versus $99.1 million, and free cash flow was $37.0 million versus $75.0 million

The filing

CompanyHaemonetics (HAE)
Form8-K, current report
Filed with the SECNov 7, 2024, 6:03 AM ET
Accession number0000313143-24-000060

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 07, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.